Sterling Investment Advisors (Pennsylvania)’s Arbutus Biopharma ABUS Stock Holding History

Sterling Investment Advisors (Pennsylvania)’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-4,000	Closed	-$11K	–	148
2022 Q2	$11K	Hold	4,000	–	–	﹤0.01%	390
2022 Q1	$12K	Hold	4,000	–	–	﹤0.01%	413
2021 Q4	$16K	Hold	4,000	–	–	﹤0.01%	387
2021 Q3	$17K	Hold	4,000	–	–	0.01%	376
2021 Q2	$12K	Hold	4,000	–	–	﹤0.01%	410
2021 Q1	$13K	Hold	4,000	–	–	﹤0.01%	381
2020 Q4	$14K	Hold	4,000	–	–	﹤0.01%	331
2020 Q3	$13K	Hold	4,000	–	–	0.01%	327
2020 Q2	$7K	Hold	4,000	–	–	﹤0.01%	365
2020 Q1	$4K	Hold	4,000	–	–	﹤0.01%	353
2019 Q4	$11K	Hold	4,000	–	–	0.01%	332
2019 Q3	$6K	Buy	+4,000	New	+$6.89K	﹤0.01%	364
2019 Q2	–	Sell	-3,000	Closed	-$11K	–	416
2019 Q1	$11K	Buy	+3,000	New	+$11.5K	0.01%	332

Other funds holding ABUS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FCM

FourWorld Capital Management New York $196M AUM 42.39% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Sterling Investment Advisors (Pennsylvania)'s ABUS Position: Q3 2022 in Review

Sterling Investment Advisors (Pennsylvania) sold out of Arbutus Biopharma (ABUS) in Q3 2022, closing a stake of 4,000 shares — an estimated $11K sold.

Sterling Investment Advisors (Pennsylvania) first reported a position in ABUS in Q1 2019 and held it in 13 quarters. The position peaked at $17K in Q3 2021. 127 funds tracked by Wall St. Rank hold ABUS as of Q3 2022.

Sterling Investment Advisors (Pennsylvania) reported no remaining Arbutus Biopharma position as of Q3 2022 after selling out during the quarter.
Sterling Investment Advisors (Pennsylvania) sold 4,000 Arbutus Biopharma shares in Q3 2022, an estimated $11K.
Sterling Investment Advisors (Pennsylvania) first reported a position in Arbutus Biopharma in Q1 2019 and held it in 13 quarters.
Sterling Investment Advisors (Pennsylvania)'s Arbutus Biopharma position peaked at $17K in Q3 2021.
127 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2022.

Based on Sterling Investment Advisors (Pennsylvania)'s 13F filing for Q3 2022, filed 3 Nov 2022.